[Treatment effectiveness of hypertension during pregnancy].
OBJECTIVE
To compare the maternal-fetal clinical intercurrences and the effectiveness of treatment in the different clinical forms of hypertensive syndromes during pregnancy (HSP).


METHODS
Medical records of 200 pregnant women with HSP were reviewed to appraise fetal intercurrences, classification of the hypertensive syndrome and use of antihypertensives.


RESULTS
Of the 200 patients analyzed, 85 (42.5%) were controls; 32 (16%) presented gestational hypertension (GH), 67 (33.5%) had Pre-eclampsia (PE), 6 (3%) had chronic hypertension and 10 (5%) cases had PE superimposed chronic hypertension (PSCH). The lowest values for gestational age, weights of the newborn and for the Apgar index were observed in the patients with PE and PSCH. Treatment did not alter the Apgar index in relation to control and non-treated GH patients. Patients with PE presented the lowest gestational age and the smallest Apgar index when compared to controls.


CONCLUSIONS
Introduction of an antihypertensive therapy during gestation was of fundamental importance for health improvement and pressure control of the pregnant woman with HSP. Nevertheless, it has been of little help for prevention of perinatal intercurrences. This was substantiated by the absence of improvement in the gestational conditions between the treated group when compared to the non-treated. Medication did not significantly improve the maternal-fetal blood flow and consequently in the birth condition of the child.
Ferrão
Mauro Henrique de Lima
MH
Departamento de Ciências Biológicas, Universidade Federal do Triângulo Mineiro, Avenida Frei Paulino no. 30, Bairro Abadia, 38025-180 Uberaba, Minas Gerais.
Pereira
Ana Carolina Lúcio
AC
Gersgorin
Heloísa Cristina Torres Soares
HC
Paula
Thales Antônio Abra de
TA
Corrêa
Rosana Rosa Miranda
RR
Castro
Eumenia Costa da Cunha
EC
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001724:Birth Weight; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D005865:Gestational Age; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D046110:Hypertension, Pregnancy-Induced / Q000175:diagnosis / Q000188:drug therapy*; D007231:Infant, Newborn; D008750:Methyldopa / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000175:diagnosis; D011247:Pregnancy; D011256:Pregnancy Outcome; D012307:Risk Factors; D018709:Statistics, Nonparametric; D013577:Syndrome
D000959:Antihypertensive Agents; D006830:Hydralazine; D008750:Methyldopa